10x Genomics, Inc.
63.97
-0.45% (최근 종가 64.26)
Company profile — from Yahoo Finance
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Company information as provided by Yahoo Finance. Check the official filings before relying on it.
Market Cap
83억 달러
PER
-
Trailing 12 months
Forward P/E
314.6배
Forward estimates
ROE
-9.4%
Return on equity
Dividend Yield
-
Beta
2.04
Volatility vs market
52주 범위에서 95% 지점입니다. 100%에 가까울수록 1년 최고가 부근입니다.
Source: Yahoo Finance
Average analyst price target
범위 $40.00 ~ $65.00 · 애널리스트 13명 · 종합의견 매수 · 출처 Yahoo Finance
Analyst rating breakdown (2026-08-01)
월가는 이 종목을 뚜렷한 매수 우위로 보고 있습니다. (매수 9 · 관망 11 · 매도 0)
Revenue trend
6억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
Net income trend
-0억 달러
2022–2025 회계연도 · 축 단위는 달러입니다.
| Year | Revenue | Operating Income | Net Income | Operating Cash Flow | Net Margin |
|---|---|---|---|---|---|
| 2025 | 6억 달러 | -1억 달러 | -0억 달러 | 1억 달러 | -6.8% |
| 2024 | 6억 달러 | -2억 달러 | -2억 달러 | 0억 달러 | -29.9% |
| 2023 | 6억 달러 | -2억 달러 | -3억 달러 | -0억 달러 | -41.2% |
| 2022 | 5억 달러 | -2억 달러 | -2억 달러 | -0억 달러 | -32.1% |
회계연도 기준 실적입니다(달력 연도와 다를 수 있습니다). 출처: Yahoo Finance. 값이 없는 항목은 채우지 않고 "-"로 둡니다.
Benzinga · 08. 25.
SeekingAlpha · 08. 20.
Prices, key stats, price targets, annual financials, filings and news above come straight from Yahoo Finance · Finnhub · SEC EDGAR, so they look the same for any US-listed ticker.
Support & resistance shows above whenever my TradingView indicator is sending alerts for the ticker. No alert is set up for this one yet, so there are no levels.
Option levels · MJM Score · REAL_BUY signals come through a Google Sheet and are still limited to the fixed watchlist. We leave them out rather than guess.